VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patientsCan a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?

ClinicalTrials.gov Published March 30, 2026 Study authors: Upstream Bio Inc. NCT06196879 ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Review the completed VALIANT phase 2 results for verekitug's effect on exacerbation rates in severe asthma.

The VALIANT study was a multicenter, randomized, placebo-controlled, parallel-group phase 2 trial designed to evaluate the efficacy and safety of subcutaneous verekitug (UPB-101) in adult participants with severe asthma. The study planned to enroll approximately 436 participants but ultimately enrolled 479. Participants were randomized in a 1:1:1:1 ratio to receive one of three verekitug dosing regimens—100 mg every 12 weeks (Q12W), 400 mg every 24 weeks (Q24W), or 100 mg every 24 weeks (Q24W)—or matching placebo. To maintain blinding, all participants received two subcutaneous injections at each dosing visit. The study consisted of a Screening/Run-In Period of approximately 4 weeks, a Treatment Period of up to 60 weeks (with a minimum of 24 weeks), and a Follow-up Period ending approximately 16 weeks after the last administration. The primary efficacy outcome was the Annual Asthma Exacerbation Rate (AAER). Other pharmacodynamic parameters assessed included lung function and asthma control. The study also evaluated the safety and tolerability of verekitug compared to placebo. The study was sponsored by Upstream Bio Inc., started on February 27, 2024, and had a primary completion date of December 16, 2025. The abstract status is listed as COMPLETED.

Imagine living with severe asthma, where a sudden flare-up can land you in the hospital. A study tested whether a new injectable medication called verekitug could help people with this condition breathe easier and have fewer of these scary episodes. The trial involved 479 adults with severe asthma. They were randomly assigned to receive either verekitug at different doses and schedules or a placebo (an inactive shot). Everyone received two injections at each visit to keep the study blind, meaning no one knew which treatment they were getting. The main goal was to see if verekitug could lower the annual rate of asthma exacerbations—those sudden worsening of symptoms that often require urgent care. The study also looked at other measures like lung function and overall asthma control, as well as the safety and side effects of the medication. The treatment period lasted up to 60 weeks, with follow-up continuing for about 16 weeks after the last dose. This research aimed to find out if this new approach could provide a meaningful benefit for people struggling to manage their severe asthma day to day.

What this means for you:

A new injectable medication was tested to see if it reduces asthma attacks and improves breathing in severe asthma.

Study Details

Study typePhase2

Sample sizen = 479

EvidenceLevel 3

Follow-up21.6 mo

PublishedMar 2026

TrialNCT06196879

View Original Abstract ↓

Status: COMPLETED | Phase: PHASE2 Condition(s): Severe Asthma Intervention(s): Verekitug (UPB-101) (DRUG), Placebo (DRUG) The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo. Detailed: This is a multicenter, randomized, placebo-controlled, parallel group study to assess the efficacy and safety of verekitug (UPB-101) administered subcutaneously (SC). A total of approximately 436 adult participants with severe asthma are planned for enrolment and will be randomized in a 1:1:1:1 ratio to receive verekitug (UPB-101) at doses of 100 mg every 12 weeks (Q12W), 400 mg every 24 weeks (Q24W), and 100 mg every 24 weeks (Q24W), or placebo administered SC. In order to maintain the blinding of different doses, all participants will receive 2 SC injections at each dosing visit. This study consists of a Screening/Run-In Period (approximately 4 weeks), Treatment Period (up to 60 weeks with a minimum of 24 weeks) and Follow-up Period (ending approximately 16 weeks after the last administr Primary Outcome(s): Annual Asthma Exacerbation Rate (AAER) Enrollment: 479 (ACTUAL) Lead Sponsor: Upstream Bio Inc. Start: 2024-02-27 | Primary Completion: 2025-12-16

VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patientsCan a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patientsCan a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?

More on Asthma

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties